EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Heterogeneity of MGMT expression in corticotroph adenomas and mechanism of acquired temozolomide resistance

Ticiana Paes iD, Richard A Feelders iD, Fadime Dogan, Anand M Iyer, Johan M Kros, Yair Schwarz, Peter M van Koetsveld, Leo J Hofland iD

The Journal of Clinical Endocrinology & Metabolism · 2026

DOI: 10.1210/clinem/dgag170 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Ticiana Paes und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Endocrinology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam 3015 GD, The Netherlands. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Antineoplastic Agents, Alkylating, DNA Repair Enzymes, DNA Modification Methylases. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Temozolomide (TMZ) can be an effective medical treatment for aggressive pituitary tumors. In case of disease recurrence following TMZ treatment, however, treatment with the drug generally does not control tumor regrowth.

Objective

This work aimed to better understand the mechanisms of resistance of corticotroph tumors to TMZ in the context of heterogeneity of methylguanine-DNA methyltransferase (MGMT) expression.

Methods

We performed immunohistochemical analysis of the MGMT expression pattern in 25 corticotroph tumors to evaluate intratumoral heterogeneity. In addition, we created in vitro models of AtT20 corticotroph tumor cells with acquired TMZ-resistance after exposure to high- and low-dose TMZ, the latter representing a clinically achievable TMZ level.

Results

MGMT immunostaining in corticotroph tumors showed a considerable heterogeneous intertumoral and intratumoral distribution pattern in 80% of tumors. In the in vitro model, high- and low-dose TMZ challenges induced a 6.3- and 3.4-fold decreased sensitivity to the growth inhibitory effect of TMZ. TMZ-induced changes in cell cycle phases were lower in TMZ-resistant cells than in vehicle-challenged cells. TMZ-resistant cells had higher Mgmt messenger RNA and protein expression and 1.8-fold higher number of Mgmt-positive cells. No difference was observed in the level of Mgmt promoter methylation.

Conclusion

Corticotroph pituitary tumors demonstrate a high intertumoral and intratumoral heterogeneity in MGMT expression. In an acquired TMZ-resistant corticotroph pituitary tumor cell model, TMZ resistance was associated with strong increase in MGMT expression and percentage of MGMT-positive cells. We hypothesize that clonal selection of high MGMT-expressing cells is involved in this acquired TMZ resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmAntineoplastic Agents, AlkylatingDNA Repair EnzymesDNA Modification MethylasesTumor Suppressor ProteinsAdenomaDacarbazineACTH-Secreting Pituitary AdenomaTemozolomideHumansCell Line, TumorFemaleGene Expression Regulation, NeoplasticMale

Stichwörter der Autor:innen

Cushing diseaseaggressive tumorspituitary tumorsresistancetemozolomide

Substanzen

TemozolomideAntineoplastic Agents, AlkylatingDNA Repair EnzymesDNA Modification MethylasesTumor Suppressor ProteinsMGMT protein, humanDacarbazine

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Endocrinology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam 3015 GD, The Netherlands.
  • Department of Internal Medicine, Roger Williams Medical Center, Providence, RI 02908, USA.
  • Holman Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, NewYork University Langone Medical Center, New York, NY 10016, USA.
  • Department of Pathology, Erasmus Medical Center, Rotterdam 3015 GD, The Netherlands.
  • Dina Recanati School of Medicine, Reichman University, Herzliyya 4610101, Israel.
  • Division of Endocrinology, Diabetes and Metabolism, Sheba Medical Center, Ramat Gan 52621, Israel.

ORCID-Profile: Ticiana Paes, Richard A Feelders, Leo J Hofland

Zitieren

APA

Paes, T., Feelders, R. A., Dogan, F., Iyer, A. M., Kros, J. M., Schwarz, Y., van Koetsveld, P. M., & Hofland, L. J. (2026). Heterogeneity of MGMT expression in corticotroph adenomas and mechanism of acquired temozolomide resistance. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag170

Vancouver

Paes T, Feelders RA, Dogan F, Iyer AM, Kros JM, Schwarz Y, et al. Heterogeneity of MGMT expression in corticotroph adenomas and mechanism of acquired temozolomide resistance. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgag170

BibTeX
@article{Paes2026,
  author = {Paes, Ticiana and Feelders, Richard A and Dogan, Fadime and Iyer, Anand M and Kros, Johan M and Schwarz, Yair and van Koetsveld, Peter M and Hofland, Leo J},
  title = {Heterogeneity of MGMT expression in corticotroph adenomas and mechanism of acquired temozolomide resistance},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  doi = {10.1210/clinem/dgag170}
}
Kostenlos starten →